<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635099</url>
  </required_header>
  <id_info>
    <org_study_id>1407-0030</org_study_id>
    <secondary_id>2017-004659-21</secondary_id>
    <nct_id>NCT03635099</nct_id>
  </id_info>
  <brief_title>This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is</brief_title>
  <official_title>Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is based on Week 12 co-primary endpoints of PASI (Psoriasis Area and
      Severity Index) 75 and sPGA (Static Physician's Global Assessment) 0/1, and overall safety
      Secondary objectives of Part 1 are to evaluate the efficacy and safety of BI 730357 through
      24 weeks of treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">July 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of ≥ 75% reduction from baseline PASI (Psoriasis Area and Severity Index) score (PASI 75) at Week 12</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Achievement of a sPGA (Static Physician's Global Assessment) score of clear or almost clear at Week 12</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of ≥50% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI50) at Week 12</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of ≥90% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI90) at Week 12</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of 100% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI100) at Week 12</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of sPGA (Static Physician's Global Assessment) clear at Week 12</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of ≥75% reduction from baseline in PASI (Psoriasis Area and Severity Index) score (PASI75) at Week 16, 20, 24</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>dose groups A to D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of an sPGA (Static Physician's Global Assessment) score of clear or almost clear at Week 16, 20, 24</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>dose groups A to D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in psoriasis symptoms evaluated using the total score on the PSS (Psoriasis Symptoms Scale) at week 12</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of a Dermatology Life Quality Index (DLQI) score of 0 or 1 at Week 12</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Dose group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 730357</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Dose group A</arm_group_label>
    <arm_group_label>Dose group B</arm_group_label>
    <arm_group_label>Dose group C</arm_group_label>
    <arm_group_label>Dose group D</arm_group_label>
    <arm_group_label>Dose group U</arm_group_label>
    <arm_group_label>Dose group V</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients. Woman Of ChildBearing Potential (WOCBP) must be ready and
             able to use highly effective methods of birth control per International Conference on
             Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year
             when used consistently and correctly from date of screening until 4 weeks after last
             treatment in this trial. A list of contraception methods meeting these criteria is
             provided in the patient information.

          -  Age 18 to 75 years (both inclusive) at screening

          -  BMI &lt; 35 kg/m2 at screening

          -  Diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at
             least 6 months before the first administration of study drug. Duration of diagnosis
             may be reported by the patient

          -  Patients must be candidates for systemic PsO therapy.Moderate-to-severe plaque
             psoriasis:

               -  BSA ≥10% and

               -  PASI ≥12 and

               -  sPGA moderate or severe

          -  Signed and dated written informed consent in accordance with ICH-GCP and local
             legislation prior to admission to the trial

        Exclusion Criteria:

          -  Nonplaque forms of PsO (including guttate, erythrodermic, or pustular), current
             druginduced PsO (including a new onset or exacerbation of PsO from, e.g., beta
             blockers, calcium channel blockers, lithium), active ongoing inflammatory diseases
             (including but not limited to Inflammatory bowel disease (IBD)) other than PsO that
             might confound trial evaluations

          -  Previous enrolment in this trial or previous exposure to BI 730357.

          -  Currently enrolled in another investigational device or drug trial, or is less than 30
             days (from randomisation) since ending another investigational device or drug
             trial(s), or is receiving other investigational treatment(s).

          -  Use of

               -  any biologic agent within 12 weeks, or

               -  any anti IL-23 biologic agent within 24 weeks prior to randomisation, or

               -  systemic anti-psoriatic medications or phototherapy within 4 weeks prior to
                  randomisation, or

               -  topical anti-psoriasis medications within 2 weeks prior to randomisation

          -  Received a live vaccination within 12 weeks prior to randomisation (visit 2), or any
             plan to receive a live vaccination during the conduct of this trial

          -  Patients who must or wish to continue the intake of restricted medications or any drug
             considered likely to interfere with the safe conduct of the trial

          -  Patients not expected to comply with the protocol requirements or not expected to
             complete the trial as scheduled.

          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,
             makes the patient an unreliable trial participant or unlikely to complete the trial.

          -  Major surgery (major according to the Investigator's assessment) performed within 12
             weeks prior to randomisation or planned within 12 months after screening, e.g., hip
             replacement

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial

          -  Any documented active or suspected malignancy or history of malignancy within 5 years
             prior to screening, except appropriately treated basal cell carcinoma of the skin,
             squamous cell carcinoma of the skin, or in situ carcinoma of uterine cervix

          -  Relevant chronic or acute infections including human immunodeficiency virus (HIV),
             viral hepatitis, candidiasis and tuberculosis. A patient can be re-screened if the
             patient was treated and is cured from the acute infection.

          -  Evidence of a current or previous disease (including known or suspected IBD,
             cardiovascular disease), or medical finding that in the opinion of the Investigator is
             clinically significant and would make the study participant unreliable to adhere to
             the protocol or to complete the trial, compromise the safety of the patient, or
             compromise the quality of the data.

          -  Any suicidal ideation, including grade 4 or 5 in the Columbia Suicide Severity Rating
             Scale (CSSRS) in the past 3 months (i.e., active suicidal thought with intent but
             without specific plan, or active suicidal thought with plan and intent).

          -  Unwillingness to adhere to the rules of UV-light protection

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Total Skin and Beauty Dermatology Center, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Krell</last_name>
      <phone>+001 (205) 933-0987</phone>
      <email>jkrellmd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Sofen</last_name>
      <phone>+001 (310) 337-7171</phone>
      <email>hsofen@ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern California Dermatology Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Soung</last_name>
      <phone>+001 (714) 547-5151</phone>
      <email>doctorsoung@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton Research</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffani Hamilton</last_name>
      <phone>+001 (770) 360-8881</phone>
      <email>drhamilton@hamiltonderm.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research PC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Weisman</last_name>
      <phone>+001 (404) 939-9220</phone>
      <email>jweisman8943@atlmedderm.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Fretzin</last_name>
      <phone>+001 (317) 516-5030-x102</phone>
      <email>DFCRGFretzin@ecommunity.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Bagel</last_name>
      <phone>+001 (609) 443-4500-x1402</phone>
      <email>dreamacres1@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Synexus</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Frankel</last_name>
      <phone>+001 (401) 454-3800</phone>
      <email>dr.frankel@riskindoc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of the Carolinas</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Schlesinger</last_name>
      <phone>+001 (843) 556-8886</phone>
      <email>skindoc@dermandlaser.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Beasley</last_name>
      <phone>+001 (605) 721-5094</phone>
      <email>Healthconcepts104@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Menter Dermatology Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Menter</last_name>
      <phone>+001 (972) 354-7993</phone>
      <email>alanmresearch@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Tyring</last_name>
      <phone>+001 (281) 333-2288</phone>
      <email>styring@ccstexas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Lee</last_name>
      <phone>+001 (281) 333-2288-x2</phone>
      <email>plee@ccstexas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Pariser</last_name>
      <phone>+001 (757) 625-0151</phone>
      <email>dpariser@pariserderm.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr Chih-ho Hong Medical Inc</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-ho Hong</last_name>
      <phone>604-953-1333 ext. 1</phone>
      <email>chihho@mail.ubc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Enverus Medical Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dr. Irina Turchin PC Inc.</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Turchin</last_name>
      <phone>506-459-1808</phone>
      <email>iturchin.bdc@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Guenther Dermatology Research Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Centre</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>SKiN Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Gooderham</last_name>
      <phone>(705) 775-7546</phone>
      <email>mgooderham@centrefordermatology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Centre for Dermatology</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mani Raman</last_name>
      <phone>905-889-2019</phone>
      <email>maniraman@tcfd.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Papp</last_name>
      <phone>519-579-9535</phone>
      <email>kapapp@probitymedical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Studienzentrum im Jahrhunderthaus</name>
      <address>
        <city>Bochum</city>
        <zip>44793</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>TFS Trial Form Support GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20537</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

